Skip to main content
SpringerLink
Log in

Rationale Behind HIPEC/Molecular and Genetic Considerations in HIPEC

  • Chapter
  • First Online:
Cancer Regional Therapy

  • 502 Accesses

Abstract

The series of molecular events comprising the metastatic cascade in peritoneal carcinomatosis is complex. The tumor microenvironment is rich in factors regulating cell proliferation, DNA repair, and senescence. Combined hyperthermia and intraperitoneal chemotherapy are utilized in conjunction with cytoreductive surgery for peritoneal surface malignancies with the intent of producing an enhanced tumoricidal effect. Cellular stress and histologic alterations occur on the molecular level with microenvironmental selective pressures shaping gene expression, DNA damage response, and protein expression. Understanding these processes may be crucial to improving patient selection and in developing potential targeted therapies. This chapter focuses on the scientific rationale behind hyperthermic intraperitoneal chemotherapy (HIPEC) as anticancer therapy as well as the molecular and genetic considerations surrounding the use of HIPEC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2(2):68–75. https://doi.org/10.4251/wjgo.v2.i2.68.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12(3):689–701.

    Article  PubMed  Google Scholar 

  3. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56. https://doi.org/10.1200/jco.2011.39.7166.

    Article  PubMed  Google Scholar 

  4. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

    Article  PubMed  Google Scholar 

  5. de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15(4):1183–92. https://doi.org/10.1245/s10434–007–9792-y.

    Article  PubMed  Google Scholar 

  6. de Bree E, Helm CW. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev Anticancer Ther. 2012;12(7):895–911. https://doi.org/10.1586/era.12.72.

    Article  CAS  PubMed  Google Scholar 

  7. Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat Res. 2007;134:21–33.

    CAS  PubMed  Google Scholar 

  8. van Baal J, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, et al. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem. 2018;66(2):67–83. https://doi.org/10.1369/0022155417742897.

    Article  CAS  PubMed  Google Scholar 

  9. Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum. World J Gastroenterol. 2016;22(34):7692–707. https://doi.org/10.3748/wjg.v22.i34.7692.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23(5):431–42. https://doi.org/10.1080/02656730701455318.

    Article  CAS  Google Scholar 

  11. Seebauer CT, Brunner S, Glockzin G, Piso P, Ruemmele P, Schlitt HJ, et al. Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells. Oncoimmunology. 2016;5(12):e1242543. https://doi.org/10.1080/2162402x.2016.1242543.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, et al. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer. 2007;6:2. https://doi.org/10.1186/1476-4598-6-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Levine EA, Blazer DG 3rd, Kim MK, Shen P, Stewart JH, Guy C, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599–606.; discussion −7. https://doi.org/10.1016/j.jamcollsurg.2011.12.028.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, et al. Prognostic molecular subtypes of low-grade cancer of the appendix. J Am Coll Surg. 2016;222(4):493–503. https://doi.org/10.1016/j.jamcollsurg.2015.12.012.

    Article  PubMed  Google Scholar 

  15. Beeharry MK, Liu WT, Yao XX, Yan M, Zhu ZG. A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol. 2016;1:77. https://doi.org/10.21037/tgh.2016.08.05.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45–57. https://doi.org/10.3978/j.issn.2078-6891.2015.111.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wagner P, Boone B, Ramalingam L, Jones H, Zureikat A, Holtzman M, et al. Histologic and immunohistochemical alterations associated with cytoreductive surgery and heated intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(Suppl 3):S588–95. https://doi.org/10.1245/s10434–015–4580–6.

    Article  PubMed  Google Scholar 

  18. Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006;6:162. https://doi.org/10.1186/1471-2407-6-162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ji Z, Sun J, Wu H, Zhang Q, Peng K, Li Y. Assessment of hyperthermic intraperitoneal chemotherapy to eradicate intraperitoneal free cancer cells. Transl Oncol. 2016;9(1):18–24. https://doi.org/10.1016/j.tranon.2015.11.015.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ji ZH, Peng KW, Li Y. Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Transl Gastroenterol Hepatol. 2016;1:69. https://doi.org/10.21037/tgh.2016.08.03.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14(8):2300–8. https://doi.org/10.1245/s10434-007-9393-9.

    Article  PubMed  Google Scholar 

  22. Wagner PL, Austin F, Sathaiah M, Magge D, Maduekwe U, Ramalingam L, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol. 2013;20(2):506–14. https://doi.org/10.1245/s10434-012-2627-5.

    Article  PubMed  Google Scholar 

  23. Zhang XL, Shi HJ, Wang JP, Tang HS, Wu YB, Fang ZY, et al. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol. 2014;20(32):11347–55. https://doi.org/10.3748/wjg.v20.i32.11347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zeng X, Shi H, Wang J, Cui S, Tang H, Zhang X. Long noncoding RNA aberrant expression profiles after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of AGC ascertained by microarray analysis. Tumour Biol. 2015;36(7):5021–9. https://doi.org/10.1007/s13277-015-3153-4.

    Article  CAS  PubMed  Google Scholar 

  25. Schaaf L, Schwab M, Ulmer C, Heine S, Murdter TE, Schmid JO, et al. Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest. Cancer Res. 2016;76(10):2868–75. https://doi.org/10.1158/0008-5472.can-15-2908.

    Article  CAS  PubMed  Google Scholar 

  26. van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, et al. Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies. Int J Hyperth. 2018;34(4):407–14. https://doi.org/10.1080/02656736.2017.1355487.

    Article  CAS  Google Scholar 

  27. Pelz JO, Vetterlein M, Grimmig T, Kerscher AG, Moll E, Lazariotou M, et al. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol. 2013;20(4):1105–13. https://doi.org/10.1245/s10434-012-2784-6.

    Article  PubMed  Google Scholar 

  28. Tu Y, Tian Y, Wu Y, Cui S. Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: indications for hyperthermic intraperitoneal chemoperfusion therapy. Oncol Lett. 2018;15(6):9385–91. https://doi.org/10.3892/ol.2018.8508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–74. https://doi.org/10.1038/nri3552.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Leijte GP, Custers H, Gerretsen J, Heijne A, Roth J, Vogl T, et al. Increased plasma levels of danger-associated molecular patterns are associated with immune suppression and postoperative infections in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Front Immunol. 2018;9:663. https://doi.org/10.3389/fimmu.2018.00663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29(1):14–24. https://doi.org/10.1038/modpathol.2015.121.

    Article  CAS  PubMed  Google Scholar 

  32. Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81. https://doi.org/10.1093/carcin/bgu227.

    Article  CAS  PubMed  Google Scholar 

  33. Davison JM, Hartman DA, Singhi AD, Choudry HA, Ahrendt SA, Zureikat AH, et al. Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms. Am J Surg Pathol. 2014;38(5):583–92. https://doi.org/10.1097/pas.0000000000000194.

    Article  PubMed  Google Scholar 

  34. Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med. 2015;13:122. https://doi.org/10.1186/s12967-015-0485-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ang CSP, Shen JP, Hardy-Abeloos CJ, Huang JK, Ross JR, Miller VA, et al. Genomic landscape of appendiceal neoplasms. JCO Precision Oncology. 2018;2:1–18. https://ascopubs.org/doi/abs/10.1200/PO.17.00302.

Download references

Author information

Authors and Affiliations

  1. University of California, San Diego, Department of Surgery, Division of Surgical Oncology, La Jolla, CA, USA

    Jula Veerapong

  2. UC San Diego Health, University of California, San Diego, Department of Surgery, Division of Surgical Oncology, La Jolla, CA, USA

    Andrew M. Lowy

Authors
  1. Jula Veerapong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Lowy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew M. Lowy .

Editor information

Editors and Affiliations

  1. City Of Hope National Medical Center, Duarte, CA, USA

    Yuman Fong

  2. Medical College of Wisconsin, Milwaukee, WI, USA

    T. Clark Gamblin

  3. City Of Hope National Medical Center, Duarte, CA, USA

    Ernest S. Han

  4. City Of Hope National Medical Center, Duarte, CA, USA

    Byrne Lee

  5. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

    Jonathan S. Zager

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Veerapong, J., Lowy, A.M. (2020). Rationale Behind HIPEC/Molecular and Genetic Considerations in HIPEC. In: Fong, Y., Gamblin, T., Han, E., Lee, B., Zager, J. (eds) Cancer Regional Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-28891-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28891-4_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28890-7

  • Online ISBN: 978-3-030-28891-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation